Background
PNZ5 is a potent and isoxazole-based pan-BET inhibitor with high selectivity and potency similar to the well-established (+)-JQ1, with a KD of 5.43 nM for BRD4(1)[1].
BRD4(1)|5.43 nM (Kd)
[1]. Montenegro RC, et al. BET inhibition as a new strategy for the treatment of gastric cancer. Oncotarget. 2016 Jul 12;7(28):43997-44012.
没有评价数据